Cytokinetics will sell percentage of royalties on heart failure drug for $90 million

The late-stage drug is being developed by Amgen and Cytokinetics.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.